Celularity Revenue Plunges 66% as Going-Concern Doubts Mount
CELU has more than doubled off its 52-week low of $0.56 on light trading volume (0.1× avg).
Summary
Celularity reported Q1 2026 revenue of $3.8M, down 66% year-over-year, with net income of $0.9M driven entirely by a one-time tax loss sale. The company reiterated going-concern doubts, liquidity strains, and Nasdaq non-compliance, while announcing a strategic refocus on placenta-derived cell therapy and a reduction in commercial headcount. This follows the late 10-Q filed September 29 that disclosed $368K cash and a $64.3M working capital deficit. The revenue collapse and cost-cutting signal a company in survival mode, with the recapitalization efforts from late September providing only a temporary lifeline. Watch for further Nasdaq compliance updates and any additional financing moves.
At the time of this announcement, CELU was trading at $1.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $51.9M. The 52-week trading range was $0.56 to $2.55. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.